Editorial Policy
This page describes how Peptides Plus decides what to publish, how it evaluates evidence, and how the Protocol Maturity Badge is assigned. It is the most important transparency document on this site — readers and clinicians using Peptides Plus as a reference should understand the editorial decisions behind every protocol summary.
Last reviewed: June 2026.
Editorial scope
Peptides Plus covers therapeutic peptide protocols with a clinical-practice orientation. The editorial focus is on three intersecting questions that health-focused readers and practitioners most often bring to this subject:
- What does the available evidence say about the protocol — dosing, administration, cycle length, and context of use?
- What is the safety profile — known adverse effects, contraindications, evidence gaps, and interaction data?
- How developed is the protocol in practice — is it established, maturing, theoretical, or observation-based?
Peptides Plus does not publish general peptide explainers, beginner-level introductions, or speculative future-of-peptides commentary. It does not cover peptides outside a therapeutic or clinical research context. The reader is assumed to already understand what a peptide is and to be asking a more specific, decision-relevant question.
The Protocol Maturity Badge
Every post on Peptides Plus carries a Protocol Maturity Badge. This is the site's primary editorial trust signal — it communicates the practical state of a protocol, not merely the type of evidence that exists. Study type (RCT, preclinical, case report) is part of the assessment; protocol maturity is the conclusion drawn from it.
The five badge levels and their assignment criteria are as follows:
| Badge | Assignment criteria |
|---|---|
| Established Protocol | Multiple human studies exist; dosing ranges are consistent across the literature; safety profile is documented with reasonable completeness. The protocol is used in clinical or practitioner settings with a degree of reproducibility. |
| Emerging Protocol | Human data exists but is limited in scale or duration; dosing ranges are still being refined; the protocol is applied in practice but the evidence base is still maturing. Meaningful uncertainty remains about optimal parameters. |
| Research Stage | Evidence is predominantly preclinical (animal models, cell culture); human data is absent or extremely limited. A protocol exists in the literature but cannot yet be called clinically ready. Theoretical basis may be strong; human applicability remains undemonstrated. |
| Case-Based | Derived primarily from case reports and practitioner observation rather than controlled study. No controlled human data. Protocol parameters come from observed clinical use, not trial design. This badge signals that the protocol exists and is being used, but the evidence structure is inherently limited by selection bias. |
| Contraindicated Areas Noted | The protocol exists and may have reasonable evidence in some applications, but specific contraindications, safety signals, or population-specific warnings are significant enough to require explicit front-matter attention. This badge does not mean the peptide is contraindicated in general — it means the safety flags are prominent enough to structure the article around them. |
The Protocol Maturity Badge is assigned by the editorial process at the time of publication and reviewed when content is updated. A post can be reclassified — most commonly from Research Stage to Emerging Protocol — when new human data changes the evidence picture. When a badge is changed, the update is noted in the post with a date.
A post can have strong underlying study quality (RCT-level evidence) and still carry an Emerging Protocol badge if dosing has not converged across those trials. Study design and protocol maturity are related but distinct assessments.
Source standards
The primary source for all factual claims on Peptides Plus is the published research literature: peer-reviewed journals, clinical trial records (ClinicalTrials.gov), and established clinical guidelines where they exist for a given compound or application. PubMed is the starting point for literature review. Where a claim originates from a study, that study is cited directly.
Secondary sources — review articles, meta-analyses — are used as overviews when they are themselves grounded in primary data, but the primary studies they summarise are confirmed and cited independently where they are materially important to a protocol claim.
Forum posts, podcast interviews, and practitioner anecdotes are not cited as evidence. They may inform the framing of a question (what practitioners observe in clinical use is a legitimate context-setter) but they do not constitute evidence of safety or efficacy and are not used as such.
Every post includes a mandatory Safety & Adverse Effects section. This section covers: reported adverse effects from the available literature, contraindications where any are documented, evidence gaps (what is not yet known about safety), and interaction data where it exists. If no adverse effects are documented in the literature, this is stated explicitly — the section is not omitted because evidence is sparse. Absence of documented harm is itself clinically relevant information, and its uncertainty is noted.
Anonymous editorial
Protocol summaries on Peptides Plus carry no individual author byline. The editorial position is attributed to Peptides Plus Editorial.
This is a deliberate choice. The protocols described here should stand or fall on the evidence and the quality of analysis — not on the perceived authority of a named individual. Attaching a name to a protocol summary creates an implicit endorsement dynamic that does not serve the reader. It also creates a conflict-of-interest surface: a named author's personal practice, commercial relationships, or professional reputation can all create subtle pressure on content that an anonymous editorial process avoids.
The editorial team behind this site is small. Anonymous attribution is accurate — no single person "authored" a protocol summary in the way a named researcher authors a paper. The content is a structured synthesis. Describing it as such is more honest than crediting a byline.
Conflict-of-interest policy
Peptides Plus does not accept funding, grants, or other financial support from peptide manufacturers, compounding pharmacies, research organisations with commercial interests in specific compounds, or any other entity whose interests could influence protocol assessments.
This site carries no advertising. It participates in no affiliate programmes. It receives no payment for including, excluding, or characterising any specific peptide or protocol. There is no mechanism by which a commercial interest could influence editorial decisions, because no commercial relationships exist.
If that changes — if any commercial relationship is ever established that touches editorial decisions — this page will be updated to describe it before the relationship affects any content.
Corrections and retractions
Protocol content may require correction for two distinct reasons: factual error (a study was misread, a figure was wrong, a claim was not supported by the cited source) or evidence update (new safety data, a new trial, a regulatory action that changes the picture for a given protocol).
Factual errors are corrected as soon as they are identified. The correction is noted within the article with a brief description of what changed. Original errors are not silently removed — readers who read the original version deserve to know the content was revised.
Evidence updates — where new data changes a protocol assessment rather than correcting an error — are handled as documented revisions. The post is updated, the year suffix in the post reflects the revision year (e.g., a post originally published with a 2025 date is revised and the heading updated to reflect 2026 data), and a revision note is added explaining what changed and why. The Protocol Maturity Badge is reassigned if the new evidence warrants it.
In the most serious cases — where new safety data establishes a meaningful risk that was not present in the original assessment — the revision takes precedence over the original content and is treated with the same front-matter prominence as the original publication. A peptide protocol that looked like Emerging Protocol in 2025 and has a documented safety signal in 2026 will carry Contraindicated Areas Noted in the updated version, with the safety data that drove that change clearly referenced.
Retractions are reserved for content where the foundational evidence base is determined to be invalid (e.g., the primary study was retracted by its journal) or where the protocol represents a safety risk serious enough that leaving even a corrected version accessible is not appropriate. Retracted content is replaced with a retraction notice explaining the basis for removal.
To report a factual error or flag new evidence relevant to a published protocol, contact contact@peptides-plus.com.
Protocol update convention — the year suffix
Protocol research moves. A protocol summary that was current in 2025 may require substantive revision by 2026 based on new trials, safety signals, or dosing consensus. To make the currency of each protocol summary explicit, post headings use a year suffix (e.g., "BPC-157 Dosing and Safety Protocol — 2026") reflecting the year through which the evidence synthesis is current.
When a protocol is updated with new data, the year suffix is updated to reflect the revision year, not the original publication year. Readers can use this to assess at a glance whether a summary is current or whether the underlying evidence landscape may have moved since publication.